Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors

Kidney Tumor Clinical Trial

— BIOPSy  

Official title:

A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05728957
• Other study ID #: 215278
• Status: Recruiting
• Start date: February 1, 2023
• Est. completion date: December 2033

Study information

• Verified date: December 2023
• Source: Loyola University
• Contact: Gopal N Gupta, MD
• Phone: 708-216-8467
• Email: gogupta[@]lumc.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this clinical trial is to better tell apart whether kidney tumors are benign (not cancer) or malignant (cancer) based on a biopsy or imaging tests and ask patients how they feel about decisions they make about treatment of their kidney tumor. The main objectives are: To estimate and compare the diagnostic accuracy of renal mass biopsy alone, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT/CT (with renal mass biopsy for hot tumors) to differentiate malignant and benign renal tumors. To estimate and compare the diagnostic accuracy of renal mass biopsy, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT/CT (with renal mass biopsy for hot tumors) to differentiate oncocytoma from chromophobe RCC. Participants will be asked to complete survey questions related to their health and kidney tumor at the start and end of the study. These can be done on paper, electronically, or by telephone.

Description:

The investigators are asking the participant to take part in this research study because they were diagnosed with a kidney tumor. Kidney tumors can be benign (not cancer) or malignant (cancer) and the investigators hope to figure out how to better tell them apart before surgery or other treatment. The investigators hope to better tell apart whether kidney tumors are benign (not cancer) or malignant (cancer) based on a biopsy or imaging tests and ask patients how they feel about decisions they make about treatment of their kidney tumor. Biopsy is a standard test to determine if a tumor is cancerous before making a treatment decision. The imaging test (99mTc-sestamibi SPECT/CT) the investigators are studying has been studied before and found to help identify benign kidney tumors. It is not approved by the Food and Drug Administration (FDA) for imaging kidney tumors. It is FDA approved for use in imaging the heart and breasts. It has been studied for use in parathyroid gland imaging. The participant will be asked to complete survey questions related to their health and kidney tumor at the start and end of the study. The participant will receive a 99mTc-sestamibi SPECT/CT scan (if they have not had one already) for research purposes. The participant will receive a biopsy of the kidney tumor (if they have not had one already) as part of their routine clinical care. The participant will then receive treatment of the kidney tumor as determined by consultation with their doctor.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 2033
• Est. primary completion date: February 2033
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants diagnosed with a clinically localized (cT1) renal tumor =7cm in size with a solid component suspicious for malignancy based on cross-sectional imaging
• Pre-existing CT images of the mass with and without contrast or planned CT to ensure both with and without contrast images of the mass have been obtained within a 365-day window
• Participants must be greater than or equal to 18 years of age
• Eligible or planned to undergo partial or radical nephrectomy as determined by primary urologist
• Eligible or planned to receive renal mass biopsy as determined by primary urologist
• Estimated glomerular filtration rate of =30 ml/min/1.73 m2 as calculated by the CKD-EPI (Chronic Kidney Disease-Epidemiology Collaboration) Equation

Exclusion Criteria:

• Participants must not be pregnant (as determined by local policy by radiology / imaging center)
• Participants must not have evidence of clinical nodal or distant metastasis.
• Participants must not have had a history of other malignancy with concern for renal metastasis.
• Participants must not have any known allergy to technetium or sestamibi.

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Kidney Neoplasms
• Kidney Tumor
• Neoplasms
• Renal Malignant Tumor

Locations

Country	Name	City	State
United States	Loyola University Medical Center	Maywood	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Loyola University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Histologic Classification (malignant vs. benign)	The classification of each tumor as malignant or benign by the diagnostic approaches of interest will be compared to the primary endpoint of malignant vs. benign based on surgical pathology or biopsy.	Until surgical extirpation or 1 year repeat biopsy
Secondary	Histologic Classification (RCC vs. oncocytoma)	The classification of each tumor as RCC or oncocytoma by the diagnostic approaches of interest will be compared to the primary endpoint of RCC vs. oncocytoma based on surgical pathology or biopsy.	30 days after surgical extirpation or 1 year repeat biopsy
Secondary	Non-diagnostic rate for renal mass biopsy	To estimate the non-diagnostic rate of renal mass biopsy.	30 days after surgical extirpation or 1 year repeat biopsy
Secondary	Patient-reported measures/outcomes related to mental health, physical health, distress, and regret	To describe patient-reported measures/outcomes related to mental health, physical health, distress, and regret for the diagnosis and management of renal tumors.	30 days after surgical extirpation or 1 year repeat biopsy